Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Theralase Technologies Inc V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops,... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

Newsfile 6 days ago

Theralase(R) Closes $CAN 2.66 Million Financing

Newsfile 9 days ago

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Newsfile March 17, 2026

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Newsfile March 10, 2026

New bladder cancer drug may sharpen radiation's aim

Trevor Abes  March 9, 2026

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Newsfile March 9, 2026

Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Newsfile March 2, 2026

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Newsfile February 20, 2026

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Newsfile February 17, 2026

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Newsfile February 10, 2026

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Newsfile February 4, 2026

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Newsfile February 2, 2026

Canadian Investment Regulatory Organization Trade Resumption - TLT

Canada NewsWire January 12, 2026

Theralase and Ferring ink deal for new bladder cancer study

Trevor Abes  January 12, 2026

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Newsfile January 12, 2026

Canadian Investment Regulatory Organization Trading Halt - TLT

Canada NewsWire January 9, 2026

Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Newsfile December 23, 2025

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Newsfile December 12, 2025

Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Newsfile November 24, 2025

Theralase(R) Investor Conference Call Reminder

Newsfile November 17, 2025

Podcasts